Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon

Gaoni, 1964, Isolation, structure and partial synthesis of an active constituent of hashish, J Am Chem Soc, 86, 1646, 10.1021/ja01062a046 Anderson, 1974, Interaction of delta9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice, J Pharm Pharmacol, 26, 136, 10.1111/j.2042-7158.1974.tb09240.x Chesher, 1973, The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice, Br J Pharmacol, 49, 588, 10.1111/j.1476-5381.1973.tb08534.x Shook, 1986, The central and peripheral effects of Delta-9-Tetrahydrocannabinol on gastrointestinal transit in mice, NIDA Res Monograph, 67, 222 Shook, 1989, Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents, J Pharmacol Exp Ther, 249, 444 Sridhar, 1984, Effect of tetrahydrocannabinol on gastric emptying of solids in humans, Gastroenterology, 86, 1265 Crawford, 1986, Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: double blind study, Med Oncol Tumor Pharmacother, 3, 39, 10.1007/BF02934575 Felder, 1998, Cannabinoid receptors and their endogenous agonists, Annu Rev Pharmacol Toxicol, 38, 179, 10.1146/annurev.pharmtox.38.1.179 Rinaldi-Carmona, 1994, SR141716A, a potent and selective antagonist of the cannabinoid receptor, FEBS Lett, 350, 240, 10.1016/0014-5793(94)00773-X Rinaldi-Carmona, 1998, SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor, J Pharmacol Exp Ther, 284, 644 Martin, 1999, Discovery and characterization of endogenous cannabinoids, Life Sci, 65, 573, 10.1016/S0024-3205(99)00281-7 Griffin, 1997, Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals, Eur J Pharmacol, 339, 53, 10.1016/S0014-2999(97)01336-8 Heinemann, 1999, Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways, Neuropharmacology, 38, 1289, 10.1016/S0028-3908(99)00056-8 Izzo, 2000, Modulation of peristalsis by cannabinoid CB, ligands in the isolated guinea-pig ileum, Br J Pharmacol, 129, 984, 10.1038/sj.bjp.0703116 Pertwee, 1996, Further evidence for the presence of cannabinoid CB1 receptors in guineapig small intestine, Br J Pharmacol, 118, 2199, 10.1111/j.1476-5381.1996.tb15663.x Coutts, 1997, Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus, Br J Pharmacol, 121, 1557, 10.1038/sj.bjp.0701301 Izzo, 1998, Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors, Br J Pharmacol, 124, 1363, 10.1038/sj.bjp.0701964 Calignano, 1997, Inhibition of intestinal motility by anandamide, an endogenous cannabinoid, Eur J Pharmacol, 340, R7 Colombo, 1998, Cannabinoid modulation of intestinal propulsion in mice, Eur J Pharmacol, 344, 67, 10.1016/S0014-2999(97)01555-0 Krowicki, 1999, Δ9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors, Eur J Pharmacol, 371, 187, 10.1016/S0014-2999(99)00165-X Izzo, 1999, Inhibitory effect of cannabinoid agonists on gastric emptying in the rat, Naunyn-Schmiedeberg's Arch Pharmacol, 360, 221, 10.1007/s002109900054 Izzo, 1999, Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB, receptors, Naunyn-Schmiedeberg's Arch Pharmacol, 359, 65, 10.1007/PL00005325 Izzo, 2000, Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil, Br J Pharmacol, 129, 1627, 10.1038/sj.bjp.0703265 Manara, 2000, Delay of gastric emptying and gastrointestinal transit by stimulation of intestinal cannabinoid CB1 receptors, Faseb J, 14, A1448 Croci, 1998, In vitro functional evidence of neuronal cannabinoid CB, receptors in human ileum, Br J Pharmacol, 125, 1393, 10.1038/sj.bjp.0702190 Ratkowsky, 1986, Choosing near-linear parameters in the four-parameter logistic model for radioligand and related assay, Biometrics, 42, 575, 10.2307/2531207 Arunlakshana, 1959, Some quantitative uses of drug antagonists, Br J Pharmacol Chemother, 14, 48, 10.1111/j.1476-5381.1959.tb00928.x Kenakin, 1997 Tallarida, 1987 Compton, 1992, Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from A9-tetrahydrocannabinol, J Pharmacol Exp Ther, 263, 1118 Zygmunt, 2000, Anandamide - the other side of the coin, Trends Pharmacol Sci, 21, 43, 10.1016/S0165-6147(99)01430-3 Di Marzo, 1999, Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators, Life Sci, 65, 645, 10.1016/S0024-3205(99)00287-8 Milligan, 1995, Inverse agonism: pharmacological curiosity or potential therapeutic strategy?, Trends Pharmacol Sci, 16, 10, 10.1016/S0165-6147(00)88963-4 Landsman, 1997, SR141716A is an inverse agonist at the human cannabinoid CB1 receptor, Eur J Pharmacol, 334, R1, 10.1016/S0014-2999(97)01160-6 MacLennan, 1998, Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors, Br J Pharmacol, 124, 619, 10.1038/sj.bjp.0701915 Izzo, 2000, Forgotten target for marijuana: the endocannabinoid system in the gut, Trends Pharmacol Sci, 21, 372, 10.1016/S0165-6147(00)01543-1